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This final report of the Lancet Commission into liver disease in the UK stresses the continuing increase in burden of liver 
disease from excess alcohol consumption and obesity, with high levels of hospital admissions which are worsening in 
deprived areas. Only with comprehensive food and alcohol strategies based on fiscal and regulatory measures (including 
a minimum unit price for alcohol, the alcohol duty escalator, and an extension of the sugar levy on food content) can the 
disease burden be curtailed. Following introduction of minimum unit pricing in Scotland, alcohol sales fell by 3%, with 
the greatest effect on heavy drinkers of low-cost alcohol products. We also discuss the major contribution of obesity and 
alcohol to the ten most common cancers as well as measures outlined by the departing Chief Medical Officer to combat 
rising levels of obesity—the highest of any country in the west. Mortality of severely ill patients with liver disease in 
district general hospitals is unacceptably high, indicating the need to develop a masterplan for improving hospital care. 
We propose a plan based around specialist hospital centres that are linked to district general hospitals by operational 
delivery networks. This plan has received strong backing from the British Association for Study of the Liver and British 
Society of Gastroenterology, but is held up at NHS England. The value of so-called day-case care bundles to reduce high 
hospital readmission rates with greater care in the community is described, along with examples of locally derived 
schemes for the early detection of disease and, in particular, schemes to allow general practitioners to refer patients 
directly for elastography assessment. New funding arrangements for general practitioners will be required if these 
proposals are to be taken up more widely around the country. Understanding of the harm to health from lifestyle causes 
among the general population is low, with a poor knowledge of alcohol consumption and dietary guidelines. The Lancet 
Commission has serious doubts about whether the initiatives described in the Prevention Green Paper, with the onus 
placed on the individual based on the use of information technology and the latest in behavioural science, will be effective. 
We call for greater coordination between official and non-official bodies that have highlighted the unacceptable disease 
burden from liver disease in England in order to present a single, strong voice to the higher echelons of government.
Introduction
In 2018’s report, we wrote optimistically of a gathering 
momentum to address liver disease in the UK, and to 
some extent this has continued. However, this final report 
of the Lancet Commission is mainly concerned with a 
series of ongoing failures in terms of the continuing 
harmful effects on health resulting from lifestyle causes. 
The broadcaster Adrian Chiles, who had learnt of the 
dangers of heavy drinking before it was too late for him 
personally, has been powerful in advocacy and was 
instrumental in the BBC Panorama programme in 
June, 2019, directed at the lobbying power of the 
drinks industry and its influence on UK Government 
policy. Sadly, the past 12 months have seen no progress 
in institution of the regulatory and fiscal measures that 
are the only proven way of controlling overall alcohol 
consumption. The government’s published Prevention 
Green Paper, entitled “Advancing our health: prevention 
in the 2020s”,1 while acknowledging the extraordinarily 
high numbers of people who are overweight or obese in 
the population, focuses mainly on tackling childhood 
obesity. Furthermore, for adults with obesity, the main 
funding commitment is for diabetes. The UK has the 
highest rate of obesity of any major nation in western 
Europe, and according to the latest report2 by the 
Organisation for Economic Cooperation and Develop­
ment, conditions fuelled by excess bodyweight soak up 
more than 8% of health expenditure in the UK, while 
cutting life expectancy by an average of 2·7 years.
National Health Service England (NHSE) has announced 
new funding for alcohol care teams in hospitals3 that 
have the highest levels of admissions due to alcohol 
dependency, but with one in five patients in UK hospitals 
consuming alcohol at a harmful level and one in ten 
alcohol dependent,1 many more hospitals will need to be 
included in the scheme.
Provision of adequate care and facilities continues to 
lag behind the continuing rise in hospital admissions of 
severely ill patients with liver disease, and mortality 
figures can only be described as unacceptable. Further 
work in 2019 has gone into developing a hospital master­
plan based on networks of district general hospitals 
linked to specialist liver centres. But, as indicated in this 
section of our report, the proposals are held up awaiting 
endorsement by NHSE. Screening for early liver disease 
with transient elastography by general practitioners is 
worthwhile for detection of previously undiagnosed 
cases of cirrhosis at a stage when treatment measures 
can be effective. However, severe cuts in community 
alcohol and addiction services, as a result of the 
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reductions in public health spending, are likely to add to 
the difficulties.
A worrying new finding relates to the occurrence of 
neurocognitive impairment in infants and children with 
liver disease, raising issues over meaningful life out­
comes. Also new to the Commission’s work this year, 
and described in detail in this report, is a ComRes poll on 
public awareness of liver disease. The one encouraging 
event in recent months was a National Institute for 
Health Research broad call for research projects of a 
translational nature in liver disease, encompassing many 
of the recommendations made by the Commission.
Low public awareness of liver disease
Polling by ComRes between May 24–27, 2019, of 2016 
British adults aged over 18 years, exposed a low level of 
knowledge about liver disease (panel 1). Participants were 
asked a series of factual statements that assessed their 
knowledge of the causes of liver diseases and other 
elements of it. Questions were reviewed by ComRes 
consultants, who ensured validity of the facts and a 
balance of questions. 646 (32%) respondents, almost a 
third, wrongly believed that the burden and number of 
deaths caused by liver disease in the UK are falling year­
on­year. Only 11% (218 respondents) correctly identified 
all three main causes of liver disease, while 26% 
(515 respondents) mistakenly thought that smoking was 
a main cause.
1793 (89%) respondents correctly identified harmful 
levels of alcohol drinking as part of the official drinking 
guidelines, but wrongly identified the weekly limit for 
men and women as over 14 units, as advised by the UK’s 
Chief Medical Officers. In addition, 1228 (61%) 
respondents considered it possible to drink higher than 
the recommended levels of alcohol for years without 
noticing any apparent harm to health. 57% of alcohol 
Panel 1: Summary of key findings of the ComRes survey
ComRes interviewed 2016 British adults aged >18 years online 
between May 24–27, 2019. Data were weighted by key 
demographics, including age, gender, region, and social grade 
in order to be representative of all British adults. ComRes is a 
member of the British Polling Council and abides by its rules.
Burden of liver disease
In the UK, the disease burden and deaths caused by liver disease are 
falling year-on-year:
• True: 646 (32%) respondents
• False: 1370 (68%) respondents
Main causes of liver disease
Which are the three main causes of liver disease?*
• Alcohol misuse: 1793 (89%) respondents
• Obesity: 813 (40%) respondents
• Viral hepatitis: 703 (35%) respondents
• All three above correctly selected: 218 (11%) respondents
• Smoking: 515 (26%) respondents
Misconceptions about alcohol misuse
You can drink higher than recommended levels of alcohol for years 
without noticing any apparent harm to your health:
• True: 1228 (61%) respondents (correct answer)
• False: 788 (39%) respondents
Estimated number of units per week as the official level for 
low-risk drinking according to the UK Chief Medical Officer’s 
guidance:
• 14 units: 313 (16%) respondents (correct answer)
• More than 14 units: 259 (13%) respondents
• Less than 14 units: 786 (39%) respondents
• Do not know: 658 (33%) respondents
How, if at all, do you consider your current level of alcohol consumption 
to impact your health? Of those who drink alcohol (n=1660)
• No impact: 593 (57%) respondents
• Negative impact: 432 (26%) respondents
• Positive impact: 230 (14%) respondents
• Do not know: 50 (3%) respondents
Steps to combat alcohol misuse and obesity
To what extent, if at all, do you support or oppose each of the 
following measures aimed at reducing obesity?
Reducing the sugar content in foods:
• Net support: 1548 (77%) respondents
• Net oppose: 161 (8%) respondents
• Neither support or oppose: 218 (11%) respondents
• Do not know: 88 (4%) respondents
Making healthy food and drinks cheaper than unhealthier ones:
• Net support: 1632 (81%) respondents
• Net oppose: 82 (4%) respondents
• Neither support or oppose: 211 (10%) respondents
• Do not know: 91 (5%) respondents
To what extent, if at all, do you agree or disagree with each of the 
following?
Labels on alcoholic drinks contain enough information on 
health risks for the public to make informed choices:
• Net agree: 860 (43%) respondents
• Net disagree: 567 (28%) respondents
• Neither agree nor disagree: 434 (22%) respondents
• Do not know: 156 (8%) respondents
More calorie information on labels of alcoholic drinks would 
help consumers make more informed choices:
• Net agree: 1051 (52%) respondents
• Net disagree: 393 (20%) respondents
• Neither agree nor disagree: 472 (23%) respondents
• Do not know: 100 (5%) respondents
*Based on prompted responses, including a range of other options included in the survey 
(not listed: inherited genetic factors, blockages to the gallbladder, lack of iron in the diet, 
and sleep deprivation).
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For more on the ComRes survey 
see https://www.comresglobal.
com/polls/foundation-for-liver-
research-public-polling/
drinkers claimed that their current level of consumption 
had no effect on their health, while only a quarter (26%) 
recognised it had a negative effect. Only 860 (43%) 
respondents agreed that labels on alcoholic drinks 
contain enough information on the health risks for the 
public to make informed choices, emphasising the need 
for more accurate and compre hensive labelling of 
alcoholic beverages.
Two in five (40%) UK adults rightly identified obesity 
as one of the three main causes of liver disease, which 
was lower than the level of knowledge about alcohol 
misuse as a key risk factor (89%). To combat obesity, 
there is overwhelming public support for reducing the 
sugar content in foods (77%) and making healthy food 
and drinks cheaper than unhealthier ones (81%). These 
findings, showing a low level of public appreciation 
of health information, should be viewed in the context 
of other similar reports.
Continuing high alcohol consumption and 
disease burden
Data from the Office for National Statistics showed that, 
in 2017, 57% of adults aged 16 years and over drank 
alcohol in the week before being interviewed, which 
equates to 29·2 million people in the UK (figure 1). 
Minimum unit pricing, which sets the lowest price that 
alcohol can be sold at 50 pence per unit, was introduced 
in Scotland on May 1, 2018. The 2019 Monitoring and 
Evaluating Scotland’s Alcohol Strategy (MESAS) report5 
found that alcohol sales in Scotland decreased by 3% in 
2018 compared with a 2% overall increase in alcohol 
sales in England, and a recently published6 modelling 
exercise found that the introduction of minimum unit 
pricing was associated with a reduction in weekly alcohol 
purchases of 9·5 g per adult per household. The purchase 
price of alcohol increased by 0·64 pence per g, which was 
higher in lower income households, targeting heavy 
drinkers of cheap alcohol. The results of the first 
12 months of minimum unit pricing on disease severity 
and mortality are likely to be confirmatory and the policy 
is estimated to result in 2036 fewer deaths during the 
first 20 years.6
Roberts and colleagues’ study7 across England and 
Wales from 2004 to 2012 reported mortality rates of 
23·4% following acute admission for alcohol­related liver 
disease and 35·4% for those with hepatic failure at 
60 days after admission, seven times higher than for 
acute admissions with stroke and eight times higher 
than for acute myocardial infarction. The early deaths 
were directly related to complications of liver disease. 
Mortality was significantly lower for patients seen by 
consultant hepatologists and gastro enterologists and for 
patients admitted to transplant centres or larger hospitals. 
At 5 years following admission, mortality was 61·8% for 
patients with alcohol­related liver disease and 57·1% for 
patients with hepatic failure. Using the same methods to 
extend the analysis to 2017, Public Health England 
showed that for England the very high 60­day mortality is 
unchanged (figure 2).
A recent meta­analysis8 showed that the true prevalence 
of alcohol­related conditions in UK NHS hospitals is 
about 20–30 times higher than the official government 
statistics (ie, 24–36 million cases per annum), most likely 
due to insufficient training of staff in the NHS to identify, 
diagnose, treat, and record the number of people with 
alcohol­related conditions.
Analysis of data from a large teaching hospital in the 
south of England showed no evidence of improvement in 
long­term survival of patients admitted for cirrhosis over 
the past 15 years (figure 3), echoing the results of an 
older study9 that showed no improvement for patients 
between 1959 and 1976. In previous reports, we presented 
data showing that in­hospital mortality for liver disease 
has consistently fallen year­on­year. But the fact that 
improvements in hospital care have not translated into 
improvements in the long­term survival of patients with 
cirrhosis is a sad reflection of overall current UK practice. 
Most patients with cirrhosis are not picked up in primary 
care but remain undiagnosed until the first admission to 
hospital with complications of cirrhosis. Around one 
third of these patients die within months of first 
presentation. The legacy system of arranging cirrhosis 
follow­up in secondary care is also not fit for purpose. An 
audit of follow­up in the cirrhosis cohort in Southampton 
(figure 3), where the hospital policy was to review every 
patient with cirrhosis at 6­monthly intervals to arrange 
endoscopy and ultrasound surveillance (in compliance 
with National Institute for Clinical Excellence [NICE] 
guidelines),10 found that, of 2126 patients with cirrhosis 
alive at the time of analysis, 494 (23·2%) had been seen 
in a clinic within the past 6 months, 1262 (23·2%) had 
not been seen for 3 years, and 859 (40·4%) had not been 
seen at all. Only 685 (32·2%) patients had a record of 
Figure 1: Self-reported drinking habits in the week before the interview in the UK from 2005 to 2017
Data from the Office for National Statistics for adults aged 16 years and over.4
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ultrasound within the past year, and 624 (29·4%) had an 
endoscopy within the past 3 years. Overall 1775 (83·5%) 
patients diagnosed with cirrhosis were missing either a 
follow­up ultrasound within 1 year or endoscopy within 
3 years; an essentially identical finding to a similar audit 
done 5 years earlier.
Using research funding from the British Liver Trust 
LOCATE project, a virtual liver clinic has been piloted over 
the past year; preliminary findings suggest that by using 
data­based recall, sharing care with general practitioners, 
and establishing virtual clinics care can be substantially 
improved.11 Liver centres must urgently put into place a 
regular audit of the efficiency of their follow­up procedures 
and make the appropriate changes to ensure equality of 
access. This requirement is particularly important for 
patients with alcohol­related liver disease who are still 
drinking and who are not likely to attend appointments if 
they have been dealt with insensitively by medical staff in 
the past. This situation can potentially be avoided when 
combined liver and alcohol follow­up is arranged through 
an alcohol care team. Over the past year in a pilot project 
as part of the LOCATE study, hepatoma and varices 
screening for a subset of patients were arranged using a 
data system via a virtual clinic.11 Preliminary indications 
are that this system is successful and cost­effective.
Alcohol care teams and community alcohol 
services
The NHS Long­Term Plan,3 published in January, 2019, 
includes a commitment to establish and optimise alcohol 
care teams in district general hospitals over the next 
5 years. NHSE and NHS Improvement will be targeting 
the worst affected hospitals with additional monies.3 
Funding will come from the clinical commissioning 
groups’ health inequalities funding supplement, working 
in partnership with local authority commissioners of drug 
and alcohol services from 2020 and 2021. In addition, a 
£4·5 million innovation fund was launched in 2018 by the 
Department of Health and Social Care for local projects 
that work with children and families affected by alcohol.12 
NHSE will apparently be providing guidance on 
implementation which, in the Commission’s view, will 
take considerable and detailed effort. 11 key components 
are essential in alcohol care teams (panel 2)13 and, in a 2009 
survey of alcohol care teams in London hospitals, only 42% 
had an alcohol sup port nurse and 10% a lead clinician;14 in 
2016, 83% of UK hospitals had alcohol support nurses,15 
and in 2019, around 60% have a clinician lead although 
many hospitals are still not staffed to provide a 7 day 
alcohol support nurse service.
The 9% of people in England with alcohol dependence 
account for 59% of all alcohol­attributable hospital 
admissions.16 Imple men tation of alcohol assertive 
outreach treatment for the estimated 54 369 patients in 
England with alcohol­attributable hospital admissions 
would cost £161 million, with cost savings of around 
£575 million—a return on investment of £3·42 for every 
£1 spent17—and also strongly correlates with the index of 
multiple deprivation (r=0·74).17 With the emphasis of the 
Prevention Green Paper on reducing health inequalities, 
the Commission’s view is that alcohol care teams and 
alcohol assertive outreach treatment should be rolled out 
to all district general hospitals with a proven patient 
burden of alcohol­related illness. This plan would help to 
achieve the UN Sustainable Development Goals, 
especially goal 10, which aims to reduce global health 
inequalities and provide a more equitable and sustainable 
future for all people by 2030.
Figure 2: Mortality following hospital admission with alcohol-related liver disease and hepatic failure from 
2004 to 2017
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Figure 3: Survival of consecutive cirrhosis admissions from the time of the first admission to University 
Hospital Southampton (2005–18)
Survival of consecutive cirrhosis admissions following first admission with a cirrhosis International Classification of 
Diseases 10 code to University Hospital Southampton categorised into 3-year cohorts. There has been no sustained 
significant improvement in survival over the time period, with long-term survival only around 40%. Data analysed by 
NS for the Lancet Commission (unpublished). 
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The alcohol and tobacco commissioning for quality and 
innovation scheme was introduced in 2017 and is being 
implemented across all inpatients in mental health, 
community, and secondary care NHS trusts.18 The latest 
data show that, overall, 25·2% of screened inpatients are 
drinking at increasing, higher risk, or possible dependent 
levels in mental health trusts, 14·2% in acute trusts, 
and 6·4% in community trusts (Robyn Burton, Public 
Health England, personal communication). These figures 
are to be compared with 25% of the general population 
who are drinking at increasing and higher risk levels and 
dependence.
Reduction in community treatment and 
addiction services
Since the introduction of the Health and Social Care Act, 
combined with cuts to the UK Government’s public 
health grant to local authorities, there has been an 
18% (£162 million) reduction in funding to community 
addiction treatment services in England, with ten local 
authorities reducing by as much as 40%, resulting in a 
22% reduction in the number of people entering 
specialist alcohol treatment, and a 52% reduction in 
access to specialist inpatient alcohol detoxification.19 
England now has less than half the level of access to 
specialist alcohol treatment compared with Scotland and 
Wales (table 1). 82% of people with alcohol dependence 
do not access specialist treatment.19
Another consequence of the cuts has been a 
48% reduc tion in the number of NHS specialist 
addiction consul tants in England and a 60% reduction 
in the number of specialist addiction trainees.21 Public 
Health England announced in March, 2019, a £6 million 
capital fund to enable local authorities to invest in 
improving access to alcohol treatment services and, 
of the 23 projects com missioned, seven comprised 
purchase of elastography machines to enable rapid 
identification of liver disease.22
Need for a comprehensive strategy to reduce 
alcohol consumption
Not only are alcohol­related deaths rising23 but, 
according to a Public Health England report published 
in 2019, an estimated one in five people are harmed by 
someone else’s drinking.24 Much evidence is available 
about the effective solutions that could be adopted, with 
action on price, availability, and marketing at the top of 
the list of interventions.25 The 50 pence minimum unit 
price of alcohol is estimated to reduce alcohol­
attributable deaths in England by 4·3% and associated 
health­care costs by 2·3%.26 Furthermore, a strong 
consensus exists among health, social care, justice, and 
civil society groups that such measures are urgently 
needed to tackle alcohol­related harm.27 A compre­
hensive alcohol strategy by the government should 
follow WHO recommendations and tackle the 
affordability, availability, and promotion of alcohol, 
aiming for a 10% reduction in harmful use of alcohol 
by 2020.28
The UK Government has repeatedly failed to grasp 
oppor tunities to take meaningful action to prevent alcohol­
related harm. Plans for a UK alcohol strategy announced 
in May, 2018,29 have been put on hold; meanwhile, the 
Chancellor of the Exchequer has made alcohol more 
affordable by cutting duty in the October, 2018, budget.30 
This decision resulted in a loss of £1 billion to the HM 
Revenue and Customs treasury, equivalent to the annual 
salaries of 40 000 nurses.31 A 2% above inflation increase 
in alcohol duty would result in 4710 fewer alcohol­related 
deaths and 160 760 fewer hospital admissions between 
2020 and 2035, according to the latest modelling report,32 
and would also raise substantial funds to support over­
stretched local public health budgets.
The government’s Prevention Green Paper,1 while 
acknowledging that alcohol harm is rising, made no 
commitment to address the major drivers of ill­health and 
inequality linked to alcohol,1 devoting only one and a half 
pages of the 78­page document to alcohol consumption. 
No actions were proposed to target the 4% of the adult 
Panel 2: Key components of alcohol care teams13
• A clinician-led, multidisciplinary alcohol care team with integrated alcohol treatment 
pathways across primary, secondary, and community care
• Coordinated alcohol policies for emergency departments and acute medical units
• A 7-day alcohol specialist nurse service
• Addiction and liaison psychiatry services
• An alcohol assertive outreach team for frequent hospital attenders
• Specialist consultant hepatologists and gastroenterologists with expertise in liver disease
• Collaborative, multidisciplinary, person-centred care
• Quality metrics, national indicators, and audit
• Workforce planning, training, and accreditation
• Research, education, and health promotion for the public and health-care professionals
• Formal links with local authority, public health, clinical commissioning groups, patient 
groups, and other key stakeholders
Number of 
patients 
accessing 
treatment for 
alcohol only*
Number of 
F10 alcohol 
hospital 
admissions†
Rate of F10 
admissions per 
100 000 population 
(>18 years of age)
Treatment 
access ratio 
(F10 admissions 
or treatment 
access)‡
Treatment 
access 
ratio20
Scotland 26 107 27 025 614·9 1·0 1·1
Wales 7678 8804 307·5 1·1 1·2
England 75 787 197 460 451·3 2·6 2·4
Northern Ireland 2577 9963 694·6 3·9 3·9
UK 112 149 243 252 467·0 2·2 2·1
*Excludes concurrent drug misuse as a reason for treatment. †Primary or secondary diagnosis of F10 mental and 
behavioural disorders due to use of alcohol as defined in the tenth revision of the International Classification of 
Diseases. This value is a proxy measure of the prevalence of alcohol dependence in the general population. ‡Note, the 
treatment access ratio (ie, the number of F10 admissions to National Health Service hospitals divided by the number of 
people accessing specialist alcohol treatment) worsened in England and the UK as a whole between 2017–18 compared 
with 2016–17. 
Table 1: Alcohol treatment access ratios across the UK in 2017–18 compared with 2016–17
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population who are the heaviest drinkers and who account 
for 30% of all alcohol consumed. The Department of 
Health and Social Care is to review the evidence for 
increasing the alcohol­free descriptor threshold from 
0·05% alcohol by volume to 0·5%.1 Such a move, however, 
will have no effect on the high­risk drinkers who are most 
in need of specialist treatment and support services.
The comments of two members of the Commission 
are quoted in full in panel 3 as a reflection of the view of 
the Commission as a whole and of many comments by 
professional bodies and agencies beyond the scope of 
this report.
Another missed opportunity for the government to act in 
the interests of public health was the failure to enforce the 
deadline on Sept 1, 2019, given to alcohol companies to 
display up­to­date and accurate information on product 
labels about the health risks associated with alcohol.38 Most 
drinks sold do not carry the latest Chief Medical Officer’s 
low risk drinking guidelines, leaving consumers unin­
formed about the latest health advice.39 In August, 2019, a 
month before the government’s deadline to display the 
guidelines on labels, the alcohol industry’s Portman Group 
announced it was encouraging its members to display the 
Chief Medical Officer’s advice on product labels40 but no 
timelines were offered for implementation.
Disease consequences of high obesity prevalence
In 2017, the prevalence of obesity in adults was 29%, 
representing a 3% annual increase, while for children in 
year 6 (age 10–11 years) and reception (age 4–5 years), the 
figures were 20·1% and 9·5%, respectively. Of particular 
concern is the widening gap in obesity prevalence 
between the least and most deprived deciles: between 
2006–07 and 2017–18, the gap in prevalence between the 
most deprived and least deprived areas increased by 
five percentage points for year 6 children.41 Obesity­
related disorders are a major contributor to hospital 
workload, with 10 660 admissions directly attributable 
to obesity and over 700 000 admissions in which obesity 
is a primary or secondary diagnosis (a 15% annual 
increase in 2019 from 2018). The 6627 admissions for 
bariatric surgery in 2017–18 are an increase of 2% over 
the previous year41 but represent treatment of less than 
2% of eligible individuals.
The National Cardiovascular Intelligence Network 
estimates that there are 4 million people with type 2 
diabetes in England, of whom 2·9 million have been 
diagnosed.42 Obesity is estimated to be responsible for 
80–85% of an individual’s risk of developing type 2 
diabetes, and the condition is responsible for more 
than 3000 amputations, over 19 000 strokes, and almost 
Panel 3: View of Commission members on the government Green Paper
In July, 2019, the Department of Health and Social Care finally, 
and very reluctantly, published its Green Paper on prevention. 
Accounts from Whitehall insiders report how the Health 
Secretary sought to withhold it and then when Theresa May, 
Prime Minister at the time, decided it should be published, 
sought to have the department’s name removed. Unusually, 
when it did appear, it was not accompanied by a press release. 
The widespread scepticism with which it was greeted33 has been 
encouraged by news that the new Prime Minister has appointed 
advisers linked to lobby groups funded by manufacturers of 
harmful products.34
The section on alcohol begins by saying that “Most people 
who drink, do so responsibly”. A study done in 2017 examined 
how the concept of responsible drinking is almost exclusively 
used by the alcohol industry and groups it funds.35 Until now, 
this term very rarely appeared in government documents. 
That study also found that it was often used in a context 
where government guidelines were being undermined and 
where the alcohol industry was portrayed as pursuing 
corporate social responsibility.
“The government’s proposals are extremely weak and ignore 
the evidence favouring population-based measures, such as 
taxation, reductions in availability, and restrictions on 
marketing which, as shown in the previous Lancet Commission 
on Liver Disease, are all strongly opposed by the alcohol 
industry.20 There are three main proposals. The first is to make 
people more aware of alcohol-induced harms through Public 
Health England’s One You campaign.36 The second is to stress 
the value of an alcohol risk assessment in the National Health 
Service Health Check, another initiative criticised for lacking 
evidence of effectiveness.37 The third is the support children 
with alcohol dependent parents although, surprisingly for a 
consultation document, this has already been launched, in April 
2018. A final section discusses collaboration with the alcohol 
industry to promote low alcohol products, without reference to 
the experience of the heavily criticised industry partnership in 
the Responsibility Deals, and in a major concession to the 
industry, promises to review the potential to redefine ‘alcohol 
free’ to allow up to ten times the current level of alcohol. In 
summary, this is a document that could easily have been 
written by the alcohol industry and is almost wholly devoid of a 
public health perspective.”
Martin McKee, Professor of European Public Health, London School 
of Hygiene & Tropical Medicine
“The Government’s recent Prevention Green Paper is framed 
in terms of individual responsibility and personalised 
approaches, diverting focus away from the commercial and 
structural drivers of ill health in the population that so 
urgently need to be tackled. However, there are some positives 
including proposed actions on obesity which represent solid 
work by the Department of Health and Social Care and Public 
Health England obesity teams but it goes nowhere near far 
enough.”
Harry Rutter, Professor of Global Public Health, University of Bath
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15 000 myocardial infarctions every year.43 At least 
10 000 people in the UK have end­stage renal failure as a 
consequence of their diabetes and more than 1700 have 
their sight seriously affected by their diabetes each year. 
Type 2 diabetes incurs almost £9 billion of costs to the 
NHS annually, around 9% of the total NHS budget.44 Of 
particular concern is the marked increase in prevalence 
in children and young adults, with 745 people under 
age 25 years reported as having type 2 diabetes in 
England and Wales in 2017–18.45 End­stage non­alcoholic 
fatty liver disease is a growing clinical problem in the 
UK, placing major challenges on the NHS. In particular, 
cases of non­alcoholic fatty liver disease with decom­
pensated cirrhosis are rising such that they are now also 
posing an increasing burden on transplant services.46
The outgoing Chief Medical Officer’s final report, 
published in October, 2019, made clear the magnitude of 
the challenge faced to achieve the government’s ambition 
to halve child obesity by 2030. The report provided 
49 wide­ranging recommendations designed to drive 
fundamental changes in the envi ronments that shape 
our dietary and physical activity behaviours.47 Achieving 
the child obesity target will involve a much greater 
regulation of the food industry, major restrictions on 
advertising and marketing of unhealthy products, and 
transforming our towns and cities to create safe, 
appealing environments in which children can walk, 
cycle, and play.47 The Department of Health and Social 
Care has proposed several actions48,49 in Chapter 2 of the 
2018 Child Obesity Plan,50 including policies to reduce 
both total calorie consumption and sugar intake, and to 
restrict advertising and marketing of unhealthy food to 
children. However, at the time of publication, these were 
still under consultation and had not yet been implemented. 
The 2019 Green Paper on Prevention1 contains a range of 
proposals, including labelling, food refor mulation, 
weight management services, and physical activity 
promotion, but gives little guidance on how these will be 
translated into effective policies, which will require much 
more intensive policy action than has been seen to date.51 
The only new regulatory commitment was to consult on 
ending the sale of energy drinks to children younger 
than 16 years of age.
The persistent framing of obesity as merely the result 
of individual choice needs to be challenged. Because 
decisions about both diet and physical activity are 
ultimately made by individuals, the choices available to 
people depend on many factors. Those behavioural 
decisions are primarily driven by environments that 
promote the overconsumption of food and under­
expenditure of energy. Equitable reductions in prevalence 
and consequent health benefits will only be achieved and 
sustained by tackling obesogenic environments.
Marketing of unhealthy food and alcohol
Unequivocal evidence shows that the marketing of 
unhealthy food to children leads to childhood obesity,52 
and that marketing of alcohol leads to an uptake of 
drinking and increased consumption in young people.53 
Similar evidence for the marketing of cigarettes and 
smoking in young people led to comprehensive and 
effective global bans on tobacco as part of the 
International Framework Convention on Tobacco 
Control.54 By contrast, the food and alcohol industries 
have been allowed to self­regulate despite evidence that 
this does not effectively reduce childhood exposure to 
adverts.55 In an increasingly digital age—children aged 
12–15 years are online for an average of 21 h each week 
in the UK56—teenagers are exposed to promotional 
activities, which include paid­for advertisements, product 
placement, content sharing by peers, or the activities of 
social media influencers. These targeted messages are 
then narrowcast to mobile devices without parental con­
trol or oversight. Young people cannot always recognise 
these marketing tactics as having a commercial goal or 
distinguish them from non­commercial content.57 The 
spend on digital marketing has increased year­on­year, 
with 2016 receiving the largest share of advertising 
spending in the UK.58
Social media and other operators have created sophis­
ticated datasets to target consumers. However, between 
the commercial operators with products to sell and their 
young target audience, marketing messages disappear 
into a black box marketplace in which individual mes­
sages are sold on by a myriad of intermediate agencies—
supply­side platforms, data exchanges, and demand­side 
platforms—which bid for advert impres sions.59 Though 
advertising messages could be tagged and traced, there is 
no facility to do this within the marketplace. Effective 
forms of age verification do exist but these are not used to 
filter marketing traffic, with the result that no­one knows 
if a marketing message is seen by a child or an adult.
Earlier in 2019, WHO published an outstanding 
report59 including a pragmatic solution—the CLICK tool, 
which provides the conceptual framework needed to 
understand and monitor exposure of children to digital 
messages.52 Along with estimating exposure, WHO states 
there should be effective age verification and message 
tagging, coupled with effective regulation. Policy makers 
need to be made aware that the digital marketplace in the 
UK is almost entirely unregulated and mandatory 
government measures to reflect this unique environment 
are urgently needed.
Obesity as a cause of common cancers
Most cancer types have multiple risk factors, with nearly 
four in ten (37·7%) cases of cancer in 2015 in the UK 
attributable to known risk factors.60 Moreover, 49% of 
primary liver cancers (around 2800 cases) are preventable. 
Being overweight (body­mass index 25–29·9) or obese 
(body­mass index 30+) contributes the highest proportion 
of liver cancers (around 1300 cases annually) and is 
second only to smoking as the leading preventable cause 
of cancer in the UK, with alcohol consumption ranking 
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sixth.60 Furthermore, being overweight or obese has a 
definite causal link with 13 cancer types—namely, breast, 
bowel, oesophagus, kidney, liver, pancreas, uterus, oral, 
ovary, myeloma, and thyroid. Alcohol consumption is 
linked to seven cancer types,61,62 with obesity having a 
synergistic effect and adding to the risk of breast, bowel, 
liver, and oesophageal cancer.63,64 The other three cancer 
types—mouth, upper throat, and larynx—have a specific 
and distinct association with excess drinking.
Planned proposals to improve hospital-based care
The Hepatobiliary Clinical Reference Group, which 
advises NHSE on the management of patients with 
advanced liver disease, has made several recom­
mendations for major changes in response to the 
increasing volume of patients with cirrhosis and the 
variation in outcomes between providers. The complexity 
of managing patients with acute or chronic liver failure 
and decompensated cirrhosis requires an experienced, 
diverse clinical team with 24 h care, provided by specialist 
hepatologists who are supported by appropriately trained 
intensivists, radiologists, dieticians, nurses, and pharma­
cists. Ready access to liver transplantation services is 
also required. However, such services cannot be provided 
in every hospital that admits patients with cirrhosis. 
Therefore, to ensure that all patients have equal access to 
high quality of care, the Hepatobiliary Clinical Reference 
Group recommended that regional networks should 
be established with each hospital linked to a centrally 
supported specialist centre. The estab lishment of a 
comprehensive series of networks with appropriate 
funding and support is strongly recom mended by the 
Commission but the proposals continue to await 
endorse ment by NHSE, with no date for implementation.
To facilitate development of the networks, the 
Hepatobiliary Clinical Reference Group recommended a 
new service specification for specialist providers of liver 
services that should lead to the development of more 
targeted referral pathways. Patients with advanced liver 
disease admitted to any hospital in the country would 
receive early, algorithm­based review (including use of the 
well established so­called cirrhosis care bundle) followed 
by a discussion with the local liver lead and, if appropriate, 
with the regional liver centre. An example of this pathway 
working is in east London where a hepatology consultant 
from Barts Health NHS Trust is based at Queens Hospital 
in Romford and provides outpatient and inpatient advice 
on specialist liver care for the region. To improve provision 
of care for patients with decom pensated cirrhosis, NHSE 
has offered a new incentive scheme (commissioning for 
quality and innovation), which rewards trusts that 
introduce network­based ap proaches to the management 
of patients with cirrhosis.65 Monitoring and evaluation of 
the changes will be through a new so­called cirrhosis 
dashboard,66 which provides information on a range of 
metrics relating to the quality of care for patients with liver 
disease and will be sent to trust chief executives every 
quarter. An analysis of data from the NHSE cirrhosis 
dashboard from June, 2018, to April, 2019, showed that, 
although only 40 trusts are currently commissioned to 
provide specialist liver ser vices, a large number (over 120) 
continue to manage patients with cirrhosis; many report 
small numbers of patients—20 trusts admitted fewer than 
ten patients per quarter to high dependency units or 
intensive care units and 76 trusts admitted fewer than 
20 such patients. 7·5% of the patients with decompensated 
liver disease admitted as an emergency died in hospital 
with a mortality of 8% in non­specialist trusts, compared 
with 6·6% in commissioned, specialist centres. Emerging 
therapeutics (eg, next generation anti­inflammatories for 
alcoholic hepatitis) and technologies (including the long­
awaited development of so­called liver assist devices that 
deliver meaningful benefits) are likely to further enhance 
the differences in outcomes between high volume and low 
volume centres.
Opportunities to improve post-hospital discharge care
Patients with cirrhosis who survive an emergency 
admission to hospital with ascites are frequently read­
mitted within a month of discharge and, although some 
readmissions are inevitable because of continued disease 
progression, many are potentially avoidable. An analysis of 
120 000 cirrhosis admissions showed that ascites and 
hepatic encephalopathy were the major predictors of 
unplanned readmission at 30 or 90 days.67 Readmissions 
are often attri butable to patients’ insufficient under­
standing of their medications or early recognition of 
symptoms, and both the American Association for the 
Study of Liver Diseases and the European Association for 
the Study of the Liver guidelines emphasise the importance 
of education.68 In one study,69 only 6% of patients with 
hepatic encephalopathy and their carers understood the 
purpose of drug therapy or its side­effects, and a survey70 of 
150 patients with cirrhosis found awareness of hepatic 
encephalopathy and its treat ment was lower than for any 
other complication. The simple intervention of providing 
educational booklets on structured care after discharge 
needs to be more widely promoted by NHSE and adopted 
by hospital trusts.
Excellent results can be obtained by trained nurse 
specialists for large volume paracentesis in patients with 
diuretic refractory ascites as elective day­case procedures. 
In Cambridge, this procedure has saved over 500 bed 
days per year and is more convenient for patients. Nurse­
led paracentesis is also offered in other locations, 
including Brighton, Bristol, Cardiff, Gloucester, London, 
Newcastle, Plymouth, Portsmouth, Southampton, and 
Truro, and should be included in planned care strategies 
for all hospitals treating patients with liver conditions. 
The value of this procedure is further shown by an 
analysis done in 2018 of over 13 000 people with cirrhosis 
in their last year of life, with day­case services giving 
lower costs and a lower probability of patients dying in 
hospital.71 The use of paper­based or electronic decision 
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support tools that prompt hospital staff to follow 
guidelines has the potential to increase the proportion of 
patients discharged on appropriate medications, leading 
to fewer readmissions.67 Moreover, the comprehensive 
cirrhosis discharge care bundle now being piloted is 
another approach meriting wider scale implementation.
Failure to increase number of liver transplants
The number of liver transplants done in 2018–19 
(n=1003)72 was lower than the 2017–18 total of 1043. 
Disap pointing also, given the potential for machine 
perfusion to increase the number of organs used, only 
8% (n=63) of adult deceased donor first liver trans plants 
involved normothermic or hypothermic machine 
perfusion, and machine perfusion was not used in two 
centres. At the end of 2018–19, the waiting list had risen 
from 359 to 432 (an increase of 20%) and, during 2016–17, 
10% of new elective patients listed for liver transplantation 
had died or had to be removed from the list.
The 3­monthly reviews of the National Liver Offering 
Scheme introduced in March, 2018, for brain death donor 
organs (on the basis of a possible trans plant benefit score 
at 5 years) showed a fall in the median waiting time for 
transplantation to 39 days (from 72 days) over the 
timeframe of a year (Douglas Thorburn, Sheila Sherlock 
Liver Centre, personal communication; National Liaison 
Officers Monitoring Committee report, unpublished). 
However, the acceptance rate of offers made through the 
scheme to specific matched recipients was lower than 
predicted, at 30%. Furthermore, the proportion of brain 
death donor livers not accepted for named recipients 
increased from 8% to 28% over the timeframe of a year. 
New patients added to the waiting list since the inception 
of the scheme in 2018 are more likely to be transplanted 
and, as predicted by the modelling exercise, there is a 
trend towards older patients undergoing transplantation 
and a reduction in patients with hepato cellular carcinoma 
receiving transplants.73
Results of the soft opt­out legislation introduced in 
Wales in 2018 are also disappointing, with no increase in 
the number of donor organs, though there has been an 
increase in donor consent rates by families which now 
exceed those in England. The implementation of opt­out 
in England in spring, 2020, together with a wider uptake 
of organ perfusion strategies to increase organ use, 
presents an opportunity to tackle unmet needs for liver 
trans plantation (eg, service evaluations on chronic liver 
failure, hilar cholangiocarcinoma, and neuroendocrine 
tumours) but, as yet, no definite proposals have 
been agreed.
There is no approval for additional liver transplant 
centres to increase transplant capacity. NHSE is con­
sidering applications from aspirant market entrants to 
replace or add to the existing providers. Several new 
centres, including Plymouth, Oxford, and Liverpool, are 
working towards this goal but none are as yet in place. 
Although overall results of transplant procedures show 
1­year survival rates of 96–97%, the demand for 
transplantation is not being met as well as it could be.
Major vacancies in workforce of consultant 
hepatologists and specialist nurses
The goal for an effective specialist hepatobiliary service 
is to have two hepatologists serving 250 000 people or 
0·8 whole time equivalent per 100 000 population. Based 
on estimates from 2017, 221 hepatologists (or 306 gastro­
enterologists with an interest in hepatology) are leading 
these specialist services, although the number of hepa­
tologists per 100 000 population is variable across 
Scotland (0·39), England (0·35), Northern Ireland (0·22), 
and Wales (0·08). Optimising levels of consultant 
hepatologists requires an increase to 528 whole time 
positions per 100 000 population, equivalent to 222 more 
posts. For this target, liver appointments (and funding) 
will need to be prioritised and the rate of consultant 
expansion improved beyond 1·6–4·9% annually for 
gastroenterology, as seen since 2009. Concerns also exist 
about the number of transplant surgeons that will be 
needed to expand the capacity of existing and new 
programmes, with availability of a greater number of 
donor organs.
For more than a decade, speciality training and 
accreditation in hepatology has lagged behind that for 
gastroenterology. The ratio of specialist trainees in 
hepatology to luminal gastroenterology trainees should, 
it is recommended, be increased from the current one 
in three ratio, thereby enabling NHS trusts to prioritise 
the filling of vacant posts. Even wider variation exists 
across the UK in the number of liver nurse specialists 
whose remit needs to be expanded to include day­case 
paracentesis and transient elastography services at the 
interface of primary and secondary care.
Detection of early disease by screening in 
primary and community care
The online toolkit for general practitioners,74 coordinated 
by the Royal College of General Practitioners and funded 
by the British Liver Trust, continues to evolve with 
the 2019 addition of detailed general practitioner 
commissioning recommendations for decision makers. 
The online toolkit also includes, as high lighted in a 
national general practitioner practice mailout, easily 
accessible information on the latest national guidelines 
for interpretation of liver blood tests75 and for use of 
transient elastography (Fibroscan) or Enhanced Liver 
Fibrosis measurement of fibrosis based on alcohol use 
disorders identification test scores. The updated toolkit 
also includes so­called quick link buttons for easy access 
to guidelines or tools during general practitioner 
consultations. Incentivising evidence­based care as well 
as working with newly formed general practitioner 
primary care networks, which can access central funding 
for social and lifestyle prescribing, represent further 
strong recommendations by the Commission.
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Inclusion of the early detection programme in an 
updated NHS Health Check, in line with NICE guideline 
NG50,10 will add substantially to the value of these health 
checks. Exemplar proven models of care include the 
prize­winning Scarred Liver Project (panel 4) in 
Nottingham and the Southampton primary care liver 
pathway (figure 4),77 which has also led to a reduction in 
hepatology referrals. These models need to be rolled out 
more widely in an effective context across the country, as 
does the Tayside programme of Intelligent Liver Blood 
Tests which, when increased serum transaminase or 
other abnormalities are found, also tests for a raft of 
likely causes and the most likely diagnosis is fed back 
directly to the requesting general practitioner.78 Each of 
the successful local schemes for earlier diagnosis have 
led to a reduction in unnecessary referrals to hospital­
based consultant clinics with consequent cost savings. 
Showing the effects on survival and state of health will 
require larger cohorts and longer periods of follow­up.
Combination of potential risk factors for liver disease in 
a primary care sample
Given the evidence supporting an additive, synergistic 
interaction between raised body­mass index and alcohol 
consumption in the development of liver disease,79 
knowledge of the co­occurrence of both factors is of 
considerable relevance to health screening and public 
health policies. The Health Improvement Network, a 
large, representative database containing anonymised, 
electronic medical records from over 700 general 
practices, was used to identify the occurrence of higher 
risk (operationalised as 35 and 50 units for women and 
men) drinking, raised body­mass index, and both risks 
combined in an adult sample attending a general 
practitioner appointment in the financial year 2017–18 
(Clive Henn, Public Health England, personal 
communication). Over 50 000 patients were identified 
who could benefit from a brief alcohol use disorder iden­
tification test and 1500 patients were both obese and 
drinking at high risk levels. True levels were thought to 
be substantially higher because there was a large 
amount of missing data referring to levels of alcohol 
consumption. Such individuals, with their substantially 
increased risk of liver disease, should be prioritised for 
screening and management measures.
Outcomes in children with liver disease
Death from liver disease in children is a rare outcome 
with mortality as low as 5% in the UK and mainly for 
patients who were not candidates for liver transplantation, 
or as a result of untreatable complications developing in 
later years after trans plantation. An audit of all deaths 
occurring within the three UK paediatric liver centres 
between 2014–18 iden tified 137 deaths, 28 (20%) of which 
had undergone liver transplantation. Only four (3%) had 
died of conditions unrelated to their liver disease. 
76 (55%) of the 137 deaths were unexpected and these 
deaths indicate an important organisational issue, with 
54% of deaths occurring outside the centres. We 
recommend that all patients attending the three specialist 
centres should be reviewed for risk of death in childhood, 
allowing more focused treatment measures and to aid the 
planning of palliative care.
Although patient survival and graft survival continue 
to be excellent, these patients have poorer cognitive 
ability, inferior educational achievement, and employ­
ment out comes following transplantation, which is a 
major, emerging concern. In a systematic review,80 
67% of children with liver disease and 82% of children 
Panel 4: The Scarred Liver Project
The Nottingham pathway (also called The Scarred Liver Project) continues to attract a 
substantial number of referrals (>3000 since inception in 2016) with diagnosis of 
clinically significant liver disease (>20% with a liver stiffness as measured by transient 
elastography >8kPa, approximately 10% cirrhosis). The pathway has evolved to allow 
general practitioners and patients greater access to transient elastography based on risk 
factors alone. Any patient with type 2 diabetes, obesity, incidental fatty liver on 
ultrasound, and a BARD* score >1, or alcohol excess can now have transient elastography 
without the need for previous liver blood tests. Supported by the local Academic Health 
Sciences Network, the pathway has been adapted for trials in other areas included within 
community drug and alcohol services in Chesterfield and within a regional primary care 
super-practice (that serves a population of 200 000 people). The forward focus is on 
developing the brief lifestyle advice provided to all patients into a more supportive and 
sustainable behaviour change intervention.76
*The BARD score is based on various elements (body-mass index ≥28=1 point, AAR (AST to ALT ratio) of ≥0·8=2 points, diabetes 
mellitus=1 point) to form an easily calculated composite score for predicting advanced fibrosis.
For more on the Scarred Liver 
Project see https://www.
scarredliverproject.org.uk/
Figure 4: Hepatology-based referrals versus community-based referrals in Southampton Primary Liver Care 
Pathway from 2015 to 2019
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who underwent liver transplantation showed low 
average or abnormal scores on specific subscales of 
cognitive and behavioural measures. Whereas neuro­
development is negatively affected by longer dura tion of 
the disease and waitlist time, liver transplantation might 
not correct the impairment.81,82 In addition, overall 
health­related quality of life is inferior and prevalence of 
mental health problems, particularly in adolescents and 
young adults, is higher compared with the general 
population.83,84 Lower educational attainment and 
special educational needs, present in 42% of paediatric 
liver transplantation survivors, are likely to affect the 
dev elopment of self­management skills, including 
adherence to treatment, typically expected in an adult 
health­care setting. Employment figures, regarded as a 
health outcome, are inferior compared with the general 
population (table 2). The Commission recommends 
that more attention should be given to the concept of 
so­called meaningful survival—a state of complete 
physical, mental, and social wellbeing and not merely 
the absence of disease.
Latest situation in other UK nations
Following introduction of minimum unit pricing in 
Scotland in 2018, annual sales per adult, at 9·9 L of pure 
alcohol,5 are now at the lowest level since the data series 
began in 1994. In 2016, sales per adult in Scotland were 
17% higher than in England and Wales whereas, in 
2018, this gap had narrowed to 9%. A continuing issue 
is that sales data for Scotland, as with the rest of the UK, 
are not comprehensive and some retailers—including 
the discount supermarkets—do not submit data to 
market research firms. Scottish Health Action on 
Alcohol Problems has called for a system in which there 
is a legal requirement for sales data to be provided. In 
2018, which included 8 months of minimum unit 
pricing, there was a 4% fall on alcohol­related liver 
disease deaths, although the overall alcohol specific 
deaths showed a rise of 1%.85 There was a 3% reduction 
in alcohol sales in Scotland in 2018. The 2019 mortality 
data, which will become available by mid­2020, would 
be expected to have fallen. Zhao and colleagues,86 
working with data from Canada, estimated that the full 
effect of price increases on mortality will only be seen 
after 3 years.84
With the early identification of liver fibrosis funda­
mental to reducing progression of cirrhosis, the Scottish 
Government has adopted the Tayside piloted intelligent 
Liver Function Test system referred to in the detection of 
early disease by screening in primary and community 
care, which is now being rolled out across Scotland.
In Wales, the implementation of legislation for a 
minimum unit price has been delayed because of an 
objection made to the European Commission by Portugal 
and the plan is to introduce it in early 2020. New 
legislation in Northern Ireland is not expected until the 
devolved government is re­established.
Conclusions
The underlying aim of this report is to emphasise again 
the important areas that need to be tackled because of 
the continuing rise in health burden from liver disease 
as a consequence of lifestyle issues of excess alcohol 
consumption and obesity (panel 5). The report again 
stresses the present need for fiscal regulatory measures 
by government if excessive consumption of alcohol and 
food is to be reduced and lives saved. The first results of 
the introduction of a minimum unit pricing in Scotland 
confirmed how specifically targeted the minimum unit 
pricing is on heavy drinkers, with a substantial decrease 
in sales of high strength, low cost alcohol products (in 
particular cider and beer), whereby the value of the 
alcohol duty escalator was shown previously over a 
5­year period. The latest report of Russia’s alcohol 
policy, with improvements in survival expectations, is 
evidence of the effectiveness of fiscal measures targeting 
price, avail ability, and marketing to reduce alcohol 
consumption.87 The finding that the levy on the sugar 
content of drinks is giving less than half the anticipated 
revenue to the exchequer because of reformulation of 
products by the industry also shows what is achievable 
by fiscal initiatives.
In education 
(%)
Unemployed 
(%)
Employed 
(%)
Paediatric liver transplant recipients (n=92) 39 25 36
Paediatric liver transplant recipients >21 years of age (n=72) 32 26 42
*Data from Kings College Hospital (London, UK). (Median age 23·2 years, range 18·9–28·7.)
Table 2: Employment outcome in paediatric liver transplant recipients*
Panel 5: The Commission’s key messages and priorities for 2019–20
Key messages
• There is a further increase in the disease burden from excess alcohol consumption and 
being overweight or obese
• The mortality for acutely sick patients with liver conditions admitted to district general 
hospitals is unacceptably high
• An early detection programme in general practice based on elastography is a feasible 
and logical proposition
• The public awareness of liver health hazards is extraordinarily poor, as shown in the 
2019 ComRes poll
Key priorities
• Convincing upper echelons of government of the need for fiscal regulatory measures, 
including minimum unit pricing, tax duty escalators, and a levy on food content
• Implementation by the National Health Service of a masterplan for hospitals and 
day-care treatments based on specific guideline bundles
• Further investigation into the causes of cognitive impairment and consideration of 
meaningful survival in paediatric liver disease
• Widening the effect of expert opinion on the present burden of liver disease through 
greater coordination with the Academy of Medical Sciences, the Royal Colleges, and 
the Royal Society of London
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In the Commission’s view, without fiscal and regu­
latory measures, the chances of achieving 5 extra years 
of healthy living, as targeted by the Secretary of State for 
Health and Social Care, is very unlikely. Furthermore, 
given the extraordinarily poor awareness of liver disease 
by the public highlighted by the 2019 ComRes survey, 
putting the entire responsibility on the individual 
to control lifestyle excesses, as recommended in the 
government’s Prevention Green paper, is unlikely to be 
successful in comparison with population­directed 
regulatory initiatives described in the Commission.
The latest unacceptably high mortality figures given in 
the report for severely ill patients with liver conditions 
admitted to district general hospitals is an urgent 
reminder of the need for NHSE to implement the 
master plan for hospital services based on regional 
specialist centres, each linked to networks of district 
general hospitals through operational delivery networks. 
Along with this requirement is the need for a wider use 
of discharge care bundles for guiding further treatment 
on an outpatient basis and for reducing the high rates of 
hospital readmission. The effectiveness of several locally 
driven schemes based on the availability of elastography 
also shows a way forward for the earlier detection of liver 
disease in general practice. The introduction of appro­
priate financial incentives for inclusion of elastography 
as part of the health check would ensure wider uptake 
and is strongly endorsed by the Commission.
Finally, the financial appraisals by the Commission 
show how costly the health burden is to the country, and 
highlight the savings that would be obtained from the 
fiscal measures suggested. These additional factors should 
also be a powerful influence for getting recommendations 
accepted by the higher echelons of government.
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